CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
18 Years and older, Male and Female
CB10A (primary)
NCI-2021-04061
Summary
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and
immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma
after lymphodepletion consisting of cyclophosphamide and fludarabine.
Objectives
This clinical trial is a first-in-human, Phase 1, multicenter, open-label evaluation of
safety and emerging efficacy of CB-010 in adults with relapsed/refractory B cell
non-Hodgkin lymphoma. The study is conducted in two parts: Part A is dose escalation
following a 3 + 3 design, with sequential, prespecified, increasing doses. Part B is the
expansion portion where patients will receive CB-010 at the dose determined in Part A.
Eligibility
- Age greater than or equal to 18 at the time of enrollment
- Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care
- Eastern Cooperative Oncology Group performance status 0 or 1
- Adequate hematologic, renal, liver, cardiac and pulmonary organ function
Treatment Sites in Georgia
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.